FLGT

Fulgent Genetics, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Fulgent Genetics, Inc. on May 21, 2018, covering events occurring on May 18, 2018. The report details the outcomes of the Company's 2018 Annual Meeting of Stockholders held in El Monte, California.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and equity plan amendments rather than financial performance data.

Material Changes and Corporate Actions

• Stockholder Approval: Stockholders approved an amendment to the 2016 Omnibus Incentive Plan, increasing the number of shares reserved for issuance by 2,000,000.
• Director Elections: Four directors were elected to one-year terms: Ming Hsieh, John Bolger, James J. Mulay, and Yun Yen.
• Accounting Firm Ratification: Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
• Voting Participation: Of 17,877,168 shares outstanding, 16,670,862 shares (93%) were present, constituting a quorum.

Voting Results Summary

Guidance, Risks, and Unusual Items

The filing contains no management guidance, outlook, or discussion of risks and contingencies. The primary unusual item is the significant increase in the share reserve for the incentive plan, which was previously approved by the Board pending stockholder approval.

Investor Verification Checklist

• Verify the impact of the 2,000,000 share increase on potential future dilution.
• Review the full text of the Amended and Restated 2016 Omnibus Incentive Plan (Exhibit 10.1) for specific vesting and grant terms.
• Confirm the tenure and background of the newly elected directors.
• Check subsequent filings for the Company's actual financial performance for the period ending December 31, 2018.